6-K ·Filed May 11, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago SEC0001575872-26-000280
Notable filing: 6-K
Actionable Insight • Neutral

Routine ESOP grant with no immediate trading implications. Monitor next quarterly filing for potential modest dilution impact from option exercises, though 3-year vesting makes this a distant consideration.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
RDY ▼ -7.61% at T+60d
NEUTRAL call ✗ call lost -7.61% · α vs SPY -12.00% · entry $13.14 → $12.14
Entry anchored
May 11, 12:47 PM ET
via exchange tick
T+1d
-5.17%
call -5.17% · α -5.04%
$12.46
settled 5mo ago
T+5d
+3.50%
call +3.50% · α +3.59%
$13.60
settled 5mo ago
T+20d
+1.75%
call +1.75% · α +2.05%
$13.37
settled 4mo ago
T+60d
-7.61%
call -7.61% · α -12.00%
$12.14
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's granted 1,192,234 stock options (816,119 Indian stock options + 376,115 ADR stock options) to eligible employees under existing ESOP schemes at an exercise price of Rs. 1,293.90 per share. This is a routine employee compensation event with no material financial impact or strategic significance.

Key Facts

  • Grant of 816,119 Indian stock options under Dr. Reddy's Employees Stock Option Scheme, 2018
  • Grant of 376,115 ADR stock options under Dr. Reddy's Employees ADR Stock Option Scheme, 2007
  • Exercise price of Rs. 1,293.90 per share for both tranches
  • 100% vesting at the end of 3 years for both option types
  • Approved by Nomination, Governance and Compensation Committee on May 11, 2026

Financial Impact

No material financial impact — standard employee stock compensation grant with 3-year vesting; dilution is minimal relative to total shares outstanding

dilution

Risk Factors

  • Minimal dilution risk from eventual option exercises over 3-year vesting period

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000280
Document: 0001575872-26-000280-index.html0001575872-26-000280
Document: 0001575872-26-000280.txt0001575872-26-000280
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access